Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Clinical trial NCT02902029 · COMPLETED
Trial details
- NCT number
- NCT02902029
- Sponsor
- University Hospital, Essen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-01
- Primary completion
- 2024-03-01
- Enrollment
- 186
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.